Abstract
Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still chal-lengina in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with beta- or alpha-emitters such as 177-Lutethium (Lu-177) or 225-Actinium ((225)A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics. clinical performance, safety and toxicity of PSMA targeted beta- or alpha-radiation therapy.
Original language | English |
---|---|
Pages (from-to) | 29-36 |
Number of pages | 8 |
Journal | Quarterly Journal of Nuclear Medicine and Molecular Imaging |
Volume | 63 |
Issue number | 1 |
DOIs | |
Publication status | Published - Mar 2019 |
Keywords
- Prostatic neoplasms
- Lu-177-PSMA-617
- Radiotherapy
- TARGETED ALPHA-THERAPY
- RADIATION-DOSIMETRY
- PSMA LIGANDS
- PRECLINICAL EVALUATION
- RADIONUCLIDE THERAPY
- PHASE-II
- BIODISTRIBUTION
- INHIBITORS
- PET
- ANTIBODY